WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Review on Drug Approval Process in Different Countries

Ms. Akansha Janardhan Shinde, Ms. Prajkta Balakshe, Dr. V. K. Redasani

Yashoda Shikshan Prasark Mandal, Yashoda Technical Campus, Faculty of Pharmacy (B Pharmacy), Wadhe Satara – 415001
akanshashinde71132@gmail.com

ABSTRACT

Before pharmaceutical items are put on the market, the drug approval procedure is a crucial regulatory route that guarantees their quality, safety, and effectiveness.

This analysis highlights the functions of the FDA, CDSCO, EMA, and TGA, among other regulatory agencies, as it looks at the medication approval processes in important regions such as the US, India, Europe, and Australia. The process encompasses several stages: preclinical research, clinical trials (Phases 0–IV), and post-marketing surveillance. Each country has distinct regulatory frameworks, submission requirements, and timelines, which influence the approval of new drugs, generics, and biologics. The study emphasizes how crucial it is to standardize regulatory requirements in order to expedite medication development worldwide while upholding strict safety and effectiveness criteria.

Key words

I. Drug approval process
II. regulatory bodies
III. FDA (Food and Drug Administration)
IV. CDSCO (Central Drugs Standard Control Organization)
V. EMA (European Medicines Agency)
VI. TGA (Therapeutic Goods Administration)
VII. clinical trials
VIII. marketing authorization
IX. post-marketing surveillance
X. global harmonization

Introduction:

Prior to being released onto the market, pharmaceutical items must adhere to strict safety, efficacy, and quality criteria. These rules are intended to safeguard the public's health by guaranteeing that medications are thoroughly assessed through preclinical research, clinical trials, manufacturing procedures, and labelling specifications. By adhering to these standards, regulatory authorities aim to prevent the distribution of unsafe or ineffective drugs, safeguard patient welfare, and promote trust in the pharmaceutical industry. The regulatory process is critical for maintaining consistent quality in drug development and fostering innovation while minimizing risks to public health.

Purpose:

Understanding regulatory frameworks, submission methods, and evaluation paths involved in the approval of medications in various countries are the p urposes of this study, with similarities and differences in global regulatory standards.

Acceptance of new drugs is currently subject to different regulatory standards in various countries. It is almost impossible to apply a unified regulatory strategy in some countries to Marketing Approval Applications (MAAS). As a result, it is important to know the legal standards of each country of MA A. [1]

The first phase of the new drug approval process is clinical research and second marketing permit. Nonclinical testing is first performed to ensure the ef ficacy and safety of the drug.

The next steps involve the implementation of four phases or phase 4 studies of clinical research. These studies have been conducted to optimize human medical dosages and ensure security and effectiveness. The drug marketing registration is then treated by responsible authorities. The drug is evaluated and approved by the responsible authority only if it is safe, effective and has a desired effect, as opposed to undesirable outcomes. The interaction betw een the adverse effects of drugs (specific groups) and other drugs should be assessed in pre-marked research studies. [2]

History

In USA

Drug research, production, and approval is a long but continuous process that involves drug discovery, clinical laboratory development, animal research , clinical research, and regulatory registration. This procedure is necessary to ensure the efficacy and safety of the drug product.
However, there were no regulations in the United States until 1906, when the Pure Food and Drug Act was approved by Congress. Shirley's change in r egulations, introduced in 1912, was introduced in 1912, and banned labeling of drug products with misleading or fraudulent claims. Food is safe and he althy

2. Safety and efficacy of drugs, biological products and medical devices

3. Makeup is purely

4. Using radiation elements allows users to resolve unnecessary radiation locations from

5. Labels for all these products are accurate and useful.

The elixylsulfanilamide disaster in the late 1930s. Security issues with liquid sulfa drug formulations were the cause of a catastrophe that demanded mo re than 100 lives. The drug had not been tested humanly before it was released. Based on these security concerns, the Federal Food, Drugs and Cosmeti cs Act (FD and C Acts) was adopted in 1938. The scope of the FD and C methods has been expanded to include medical devices and cosmetics. A signi ficant change in the FD and C laws of Kefferber Harris' drugs was passed in 1962, strengthening the security standards for new drugs and introducing e fficacy requirements for the first time. The Price Competition and Patent Time Repair Act was approved by Congress in 1984 to improve patent protect ion and compensate for patent lifetimes lost during the approval process. The act allowed the FDA to approve generics as soon as they set healthy and male bioequivalence. Additionally, the FDA has the authority to determine both prescriptions and -Counter (OTC) medications (OTC). [3]

In India

In India, the national drug regulation system of 1940 was registered and registered in India in 1940, based on the Central Drug Standards Control Or ganization (CDSCO), which was established in 1943, enrolled in India in India, India, India, India, India, India, and India. (CTRI) and the requirement f or informed permissions for inclusion in audiovisual media were two major improvements in 2008 and 2013.[4]

After significant changes with significant changes, new laws on medication and cosmetics were introduced in 2019 with various ethical commissions fo r biomedicine and sectors. Preclinical research exceptions and conditional approval of clinical research if drugs are approved in certain developed count ries. [5]

In Europe

Drug registration in Europe has changed dramatically due to changes in public health regulations and initiatives. Before the 1960s, drug approval was a decentralized process in which countries set their own requirements. The serious birth abnormalities caused by the Thalidomide Disaster (1957) (1961) led to the first EUwide legislation, Guidelines 65/65/EEC (1965), demonstrated that quality, security, and effectiveness demonstrated. State agencies w ere established to monitor approvals from the Federal Institute for Drug and Medical Devices (BFARM) in Germany and regulatory authorities for drug s and health products (MHRA) in the UK. In 1995, the central mechanisms of highrisk medical practitioners (e.g. biology and omphalamathematics) bet ween the establishment of the European Drug Administration (EMA), a decentralized/mutual recognition approach for other drugs, and regulation for th e regulation of landmark methods and cell therapy asshoes (AMMP) regulations (2007) (2007) (2007) Alley and Cell Therapeutics (2007). (2000) Provi des incentives for the treatment of abnormal illnesses. The Integration and Adaptation Path in the Real World (RWE) (2014) are two latest innovations t hat want to accelerate the permissions of uncovered needs [6]. Despite autonomous driving after Brexit, the UK MHRA continues to adhere to EMA gu idelines [7]. Future development will focus on KE-controlled drug creation and digital treatment. [8]

In Australia

Australia's drug registration regulations changed over time, switching from acceptable state oversight to a strict national framework. Before 1966, the 1 916 Law of Treatments provided only a limited regulation of imported drugs. Local products were not regulated [9]. The first thorough structure was cr eated by the 1966 Therapeutic Products Act. It requires security testing of all drugs and has established the Australian Drug Assessment Committee (A DEC) for scientific evaluation. The 1989 Therapeutic Herring Act determined the Department of Treatment Products (TGA) and set up the current two stage systems of listed drugs (requires clinical evidence) and registered drugs (requires clinical evidence) and demonstrated innovative changes. The Or phan Drug Program (1998), Provisional Entrance Route (2017), and Good Manufacturing Requirements (GMP) (1976) were one of the latter reforms th at gradually brought Australia to global norms [9]. This development shows how aggressive, risk-based regulations have replaced reactive, crisis-oriented regulations.

Overview of Drug Discovery and Drug Development

A complex procedure, drug discovery, is finding chemical therapeutics and treating diseases. To create medicines that prevent or look around the effect s of disease, researchers generally develop new medicines by learning more about the disease process. Potential drugs must be discovered, synthesized, characterized, and scrolled to discover their therapeutic effects as part of the drug development process. According to clinical research, chemicals that e xhibit promising results from these studies will take over the drug's outbreak. Drug discovery and development are expensive due to the critical resourc es needed for clinical research and research and development.

It usually takes 13 to 15 years from the time a new drug molecule is discovered to the point where it is fired for treatment of a patient. The research and development costs for each successful drug are estimated at $800 million and $51.5 billion. This number includes costs due to many obstacles. Only on e of the 4,000 10,500 connections exposed to research and development is approved.

Many connections fail and the introduction of a single drug for patients is a timeconsuming procedure that can be explained by the complexity of the R &D process. Firstclass logical and scientific minds, rich resources, stateART lab technology, and thorough project management are required for success . It also requires happiness and patience. The process of searching for new medicines ultimately leads to healing, hope and beliefs for billions of people. [10, 11]

- **Disease identification**

Before discovering a potential new drug, scientists try to grasp the disease that needs to be treated and determine the reason or cause. They try to unders tand how genes change, how this affects the proteins they encounter, how these proteins interact in live cells, how affected cells change the tissues they are found, and finally how they affect the whole patient. This information serves as the basis for treating problems. Government, academic and commer cial researchers all contribute to uncovering the genetic and cellular components that contribute to disease. [12]

- **Target identification**

Targeted drug development deals with the localization and understanding of the role of disease-
critical molecules (such proteins or genes). The goal is the goal. Drug development can be focused on improving normal pathways that are hindered by disease, or thwarting the effects of these goals. Find possible goals and adapt specific patient groups, bioinformatics, chemoformatics, and data chemistr y technologies (to adapt homology, ligands, structure-
based approaches, and treatments such as high threat screening (HTS) and MicroRray technology). [13]

- **Target validation**

As soon as a pharmacological goal is set, a thorough assessment should be performed to demonstrate that changes in the target provide the intended trea tment outcome. The massive slowdown in drug discovery is based on the difficulty of target verification. Using computer technology to accelerate this procedure significantly accelerates the step verification step. The target validation process involves examining whether changes in target function lead t o improvements or extinction of the phenotype, which is the intended outcome of treatment. Subcellular localization prediction, protein-
pathway mapping, protein protein interactions, genetic network mapping, and disease locus mapping are several methods that can be used to characteriz e silico. The initial selection of targets is based on lateral organism confirmation, protein expression, suspected binding location including disease or he alth status due to disease or provisional findings between cell location and disease or health [14]

- **Lead Identification**:

Chemical lead is a druglike, stable molecule that has strong selectivity towards its target and performs well during testing. It is simply necessary to crea te a structureactivity relationship (SAR) present in basic toxicity testing. The leads must also show their physiological effects and their effectiveness in t he experiment. It is important to understand the pharmacokinetics and potential toxicity of chemicals (PKs). Evaluation of drug capacity using tests suc h asAMES tests and cytotoxicity assays ensures that the molecule binds to its target, has a good absorption and distribution profile, anddoes not cause d amage to prevent drug development failure. [15]

- **Early Safety Trials:**

As soon as lead compounds are identified, they are run before early security tests to assess pharmacokinetics (absorption, distribution, metabolism, excr etion) and toxicity. These tests are extremely important to understand how the drug behaves within the body and whether it is certain that further develo pment will make sure to move forward. Preclinical toxicological studies can help identify potential adverse effects and develop decisions and abandon c onnections [12]

- **Lead optimization**

To develop therapeutic candidates, we improve the pharmacological properties of lead optimization in complex, nonlinear processes that change the che mical structure of validated hits. Target selectivity and affinity are maximized in lead structures. Structure
based absorption, distribution, metabolism and excretion (ADME) is supported by a docking approach. In this way, it is necessary to experimentally de monstrate the identified drug candidates to tackle diseasespecific animal models. High screening ability and ability to obtain simple, clear requirements for candidate drugs are two advantages of this dramatic change in the drug discovery process, from physiological to target approaches. This allows for l ogical drug design. [16]

- **Preclinical studies**

Nonclinical research in the course of drug development involves assessment of the security and efficacy of medicine in animal models before predicting human impact. Furthermore, preclinical experiments must be evacuated from the relevant regulatory authorities. The supervisory authority is responsib le for ensuring that research proven safe and effective is conducted safely and morally, and only approved drugs are carried out. Acceptable preclinical drug development groups have been defined. [17]

General pharmacology and toxicology are two ways to perform preclinical testing. Testing the pharmacokinetics and pharmacodynamics of drug produ cts is known as pharmacological pharmacology. Unwanted pharmacological effects must be examined in appropriate animal models and pursued in toxi cological studies. The security and efficacy of the absorption, distribution, metabolism and excretion properties of a drug are determined by pharmaco kinetic testing.These studies provide data on the absorption rates of various routes of administration. This helps in terms of distribution, dosage form sel ection, rate of metabolism, and extent that affects drug image. Half Life of Drugs provides clarification of the security profile required for regulatory ap proval.The mechanism of drug distribution shows the therapeutic effect of drugs, as drug bioavailability and affinity depend on it. The possibility of a d rug passing through several stages of biotransformation and producing metabolites is provided by drug metabolism. It is also supported to understand th e enzymes and processes involved in biotransformation. [18]

Toxicological drug studies can be conducted using in vitro and in vivo tests to assess the toxic effects of drugs. Vitro experiments can be performed to i nvestigate the direct effects on cell proliferation and phenotypic effects. Both qualitative and quantitative reviews of toxicological effects can be perfor med in vivo. With many drug species, it is important to select the right animal species for toxicity studies. In clinical studies, Vivo often examines studi es to assess pharmacological and toxicological activity, including modes of action and recommended use. [19].

- **Investigation New drug application Drug**

Before clinical development begins, developers must apply for experimental new drugs using the FDA.

- **Clinical trial**

Clinical research is conducted on human subjects to assess the security, effectiveness and best practices of medication, vaccination, and treatment. The r esearchers have developed defined methodologies for these studies. This includes choosing people, choosing doses, and establishing procedures to colle ct data. This procedure begins with the initiation of the Research New Drug (IND) process and review of previous drug data. [21]

Phases of Clinical Trials

1. Phase 0: Moderate doses are administered 10,15 healthy people to collect pharmacokinetic data without therapeutic effects. It helps you determine th e most promising drug therapy candidates. [22]

2. Phase 1:20 Use 80 healthy volunteers (or if necessary) to focus on safety and dosage. The goal is to determine safe dosages, assess side effects, and a nalyze how the drug behaves within the body

3. Phase 2: Hundreds of patients are included to assess safety and test efficacy. This phase helps improve research techniques and determine the ideal th erapeutic dose.

4. Phase 3: Use a large cohort (300 3,000 participants) to verify efficacy and pursue lasting negative impacts. Families of clinical research

In addition to providing conclusive security information, this procedure is necessary to ensure regulatory approval. After Phase 3 delivery, drug therapy will be sent to the regulatory assessment. If approved, the drug can be sold. The security and effectiveness of new therapies for general use depends on clinical research. [23]

New drug application

After completing all three clinical research phases, the sponsoring organization examines all data. If the results indicate that the experimental drug is saf e and effective, the company entered new drug application (NDA) up to 1000 pages in length. The NDA includes all data from the previous year and su

ggestions for the manufacture and labeling of new drugs. To determine whether a drug is safe and effective enough to be approved, FDA experts will ch eck all the information contained in the NDA. After careful consideration, the FDA is either 1. Give medication permission.

2. 3. Additional data or research is required prior to granting approval. Permission to Waste

The NDA review evaluated information from another group of experts reported by the FDA, the consulting committee and FDA experts. The committe e will then coordinate whether the FDA should accept the application and in any circumstances. The NDA review influenced another specialist group, t he consulting committee, presented by the FDA, to assess information from the company and FDA experts. The committee will then coordinate whethe r the FDA should accept the application and in any circumstances. [12]

Post Market surveillance

Phase 4 studies will be conducted after FDA approval for medication or medical devices. These studies are also recognized as post-marketing monitoring. This includes ongoing technical support and post approval pharmacobigil. The Phase 4 study uses a variety of observational techniques and evaluation patterns to measure the safety, cost-effectiveness and effectiveness of interventions in real-world settings. Phase-IV research can be carried out by sponsoring corporations for competitiveness or other reasons, or can be specified by the supervisory authority (e.g., la belling changes, minimizing risk management/action plans). As a result, the actual photos of drug safety cover the months and years, essentially consist ing of drug durability. After reports of prescription and over-the-counter medication difficulties have been checked, the FDA may choose to provide dosage or practical information, as well as other events for importa nt adverse reactions. [24]

Regulatory Submission Formats: The Common Technical Document (CTD)

Related documents are files submitted to obtain a new drug or new drug. A CTD is a predefined format (template) for a data presentation with an I area. It is optional in some countries.

CTD was created with the simple goal of providing standard structures for technical materials, significantly reducing the time and resources required to register human drugs and facilitating electronic submission. The CTD related documents are made up of five main sections.

Module 1: Management and prescribing information

Model 2: Module 3â5 Overview and summary

Model 3: Quality (pharmacology/toxicology)

Model 4: Non-clinical report (pharmacology/toxicology)

Model 5: Clinical research report (clinical research) [25]

Module 1

It is not only included in the CTD as it includes locally related papers such as proposed labels and applications. This article will not go further deeper a bove this module as its format and content arespecific to each regulatory authority.

Module 2

Includes CTD Summit and Overview. It starts with an overview of the drugs covering its pharmacological class, mechanism of action, and expected cli nical applications. "Quality" information (i.e., drug documents) is summarized in Module 2, along with clinical summary, non-clinical document summary, tabular summary, and non-clinical summary.

Module 3

It focuses on a pharmaceutical product's quality, including information regarding the formulation, manufacturing process, active ingredient, excipients, and pertinent controls. It gives the regulatory bodies the information they need to evaluate the product's quality and make sure it satisfies the necessary safety and effectiveness requirements.

Module 4

Also referred to as the "Non-clinical Study Reports" module, it includes all of the information and reports pertaining to pre-clinical (non-clinical) studies that show the drug product's safety, including toxicology, pharmacology, and pharmacokinetics. It is a component of the Common Technical Document (CTD), a format that is standardized for submissions related to drug registration.

Module 5

emphasizes clinical study reports, or CSRs. It provides the clinical information, including findings from human trials, required to evaluate a pharmaceutical product's benefit-risk ratio. The ICH M4E guidelines outline Module 5's format and subject matter.

The display of documents, known as marketing approval, completes the process of researching and evaluating relevant documents supporting pharmace utical products, also known as marketing (licensing, registration, approval, etc.). The legal framework that regulates this process explains the prerequisit es for submitting an application to the relevant (competent) regulatory authority, the assessment process (based on quality, effectiveness, security stand ards, security standards), reasons for approving or rejecting the application, and the situation where already granted and already recognized marketing a pprovals have already been granted. Registration documents, also known as US New Drug Registration (NDA), also known as Marketing Authorization Applications (MAAs) in the EU and other countries, are - Application documents for a ketting permit. A related document containing information incl uding drug quality, drug efficacy, drug and security features, additional control documents, obligations to use, duty to use, materials used, materials use d, and materials used, and materials used. Materials required for line analysis. Related documents are essentially included in this. For example, the US, EU and Japanese governments have been requesting CTD format (common technical documents) since 2003 and have recently requested the electronic counterpart, the Electronic Joint Technical Document (ECTD). This application will be submitted to the drug regulatory authority of the relevant countr y. It may be a specialized department within the Ministry of Health or an independent regulatory organization. (This contains only minimal information that identifies the product and its source). The FDA states that the pharmacokinetic and pharmacodynamic properties of generic drugs are the same as t hose of their brand name equivalents or fall within an acceptable bioequivalent range. Therefore, the FDA considers generics to be comparable in terms of dosage, efficacy, management methods, security, efficacy, and intended use.

The FDA literally does not use the word "identical." Rather, it is legally interpreted. After the original developer's patent protection is finished, general products will be available.

CTD forms are also required for marketing approval for generic products. Submission of MAA Applications (EU) to generics under ANDA's entry into the US is called "omitted." RLD: A certified pharmaceutical product that demonstrates the bioequivalence of new generic equivalents. The FDA publis hes an orange book, an approved drug product with a Therapeutic Equivalent Assessment (CDER).

Clear clinical research in generic medicine no longer requires clear clinical research from 1984. The new drug for import proposed for approval is CDS CO. (India).

The goal of the CTD format is to standardize the format and organization of registered documents. The thorough and well-structured advantages make electronic entry simpler, allowing for easier comparisons of cross-point applications, among other things. [26]



Figure1: The CTD Triangle

Data Formatting and Organization

Each module's documents need to follow certain formatting guidelines.

Example-

1. PDF - Portable Document Format
2. XML-Extensible Markup Language

Document Organization –

- Data should be clearly organized into folders and subfolders following the eCTD structure.

A. **Folder 1.0**: Application forms, regulatory information, etc.

B. **Folder 2.0**: Summaries (overview documents).

C. **Folder 3.0**: CMC data (Chemistry, manufacturing, controls, etc.).

D. **Folder 4.0**: Nonclinical data (toxicology, pharmacology, etc.).

E. **Folder 5.0**: Clinical trial data. (Protocols).

Validation of the Dossier

- Verify that all files, including naming conventions, document types, and general structure, adhere to the eCTD format before submitting.
- Utilize the validation resources that third-party vendors or regulatory bodies have made available such as-

i. eCTD Validator

ii. FDA's e-Submitter

iii. Lorenz eValidator

iv. EURSvalidator

v. MEDWISDOM validator

vi. MONO CTD validator

REGULATIONS OF DRUG APPROVAL PROCESS [27,28]

Applications for new drugs (NDAs) will be submitted to the corresponding regulatory authority for approval of the sale of new drugs [27]. Sponsors wil l provide preclinical and clinical testing data for analysis of drug information and explanations of the manufacturing process to obtain this approval.V arious stages of clinical trials:

Research on mice, rats, rabbits, and monkeys before clinical use

- **Phase I** comprises human pharmacology trials that estimate safety and tolerability
- **Phase II** exploratory trials are conducted to evaluate treatment effectiveness and identify short-term side effects.
- **Phase III** comprises confirmatory trials that confirm therapeutic benefits
- **PhaseIV**tested drugs are included in Phase IV according to marketing or research conducted after approval. Upon receipt of the agency, the NDA is subject to a technical screening process that ensures that sufficient data and information is submitted in all areas to justify the applic ation "registration". At the end of the review process, the sponsor can receive one of three possible measurements: • Not approvable: which includes a list of deficiencies and an explanation;

• **Approvable:** which indicates that the drug can be approved but has minor flaws that can be fixed, such as labelling changes and a potential request commitment to conduct post-approval studies

• **Approval:** this indicates that the medication is authorized.

The regulatory organization gives the applicant a chance to meet with the agency and go over the shortcomings if the activity is deemed either acceptable or not.



Figure 2: The Basic Regulation

DRUG APPROVAL PROCEDURE IN INDIA

To control the import, production, distribution, and sale of medications and cosmetics, the Indian parliament created the Drug and Cosmetic Act 1940 and Rules 1945. The Central Drugs Standard Control Organization (CDSCO) is led by the Drugs Controller General of India (DCGI).[29] The 1945 Drugs and Cosmetics Rules require adherence to the following regulations: (30).

Rule 122-A: request seeking authorization to import a new medication.

Rule 122-B: requesting authorization to produce novel medications that aren't listed in Schedules C and C1.

Rule 122-D: Manufacturing or importing a fixed-dose combination requires prior approval.

Rule 122-DA: Request for authorization to carry out clinical studies for new or investigative drugs.

Rule 122-DAB Compensation for harm or death during clinical studies is outlined

Schedule Y was added to the Drug and Cosmetics Rules 1945 by the Indian government in 1988.

Clinical research requirements and guidelines are listed in Appendix Y, updated in 2005 to adapt to globally recognized practices. The revision is a cha nge to determine the criteria and the exact role of sponsors and investigators for the PhaseI,IV test. In 2006, the clinical research was further divided int o two groups. (Japan and the European Union) and is expected to be approved in eight weeks. Category B clinical studies must be examined more close ly and approved within 16 weeks. You should also mention the date of the investigation protocol, the consent declaration, and the investigator's brochur e. Clinical research cannot be conducted without the approval of the DCGI and the Ethics Committee. The application must also be handed over to the c ommittee. To determine the best dosage people can take, negative answers and more.

Clinical stageI studies have been conducted on healthy, human participants. Ten to 12 patients at each dose level are participating in a phase II study to assess therapeutic uses and effective dose areas. The purpose of the phase-
III confirmation study is to collect information on the safety and efficacy of the drug in approximately 100 patients at 3-
4 centers. If the new drug is not sold in other countries, a Phase-III study should be conducted on at least 500 patients distributed at 10 15 facilities.

After completing the clinical study, the new drug will be registered using Form 44 to complete preclinical and clinical laboratory data. In addition to se curity and effectiveness data, you will also need detailed information on drug marketing status in other countries. Additionally, product monographs, lic ense plates, boxes, samples, test procedures, and prescribing information must be submitted [21]. The application review period is approximately 12-
18 months. This product is considered in Phase IV studies where new uses or new population groups, longterm impacts, etc. are examined after NDA a pproved and companies can distribute and promote the product.

The country has various procedures for approval of drug therapy. In some countries, a single agency is responsible for all drug regulations, including ap proval of new drugs, granting production licences, and inspecting production systems. For example, the FDA will take over all these tasks in the US. In certain countries, such as India, where this obligation is divided between states and central authorities, not all functions are carried out by a single regul atory authority. The time required to approve a CTA application is the time required to evaluate marketing permit applications, register price, registratio n process, and marketing exclusiveness. Some countries, such as the US and China, have two review processes: the usual review process and the accele rated review process. Like India, other countries only have a review process. Similarly, this format differs depending on which relevant documents wer e submitted for approval of medicinal products. Preparation of related documents in the CTD is necessary in certain countries such as the US, EU, and J apan.

Stages of approval

• Applications for clinical research to assess effectiveness and security.

• The prerequisites for approving new medications.

• Modifications to biological product quality, safety, and efficacy documentation after approval.

• Creating the quality data needed to submit a novel medicine for approval

Each country has a different process for drug approval. In certain countries, the FDA is the only agency responsible for drug regulation and controls all regulatory activities. However, in certain countries such as India, centralized and state organizations share this function as a single supervisory authority that performs all regulatory tasks. There is only one review process like India, but there are two other countries like the US. It's a standard review proce ss and an accelerated review process. Additionally, a form for detection of related documents submitted for approval of a drug.

DRUG APPROVAL PROCESS IN UNITED STATES

The US Food and Drug Administration (USFDA) is responsible for regulating all food, drug therapy, cosmetics and medical devices for people and ani mals in the United States [34]. In the United States, the USFDA protects public health by ensuring that all drug therapies are safeand effective. Development of Pharmaceutical Rights and Regulations in the United States: Founded in 1820 in the United States, Pharmacopoea (USP) has establishe d standards of medical purity and strength.

The following are important turning points in the evolution of US drug law: [34-37]

The Food and Drugs Act of 1906: It requires that the drugs' strength and purity adhere to established criteria.

Federal Food, Drug, and Cosmetic Act (1938): Following the sulphanilamide incident, laws demanding that medications be proven safe before being sold were passed.

The Kefauver-Harris: Amendment was passed in 1962 as a result of the thalidomide disaster. Manufacturers must provide evidence of the items' efficacy and safety. All businesses should notify the FDA of any negative consequences.

The 1973 Orphan Drug: Act permits pharmaceutical corporations to deduct taxes toward the development of orphan medications.

The Generic Drug Enforcement Act of 1992: deals with legal actions related to the approval of Abbreviated New Drug Applications (ANDAs).

If the findings of preclinical trials show that the medication is safe, an application is made to the FDA to start human clinical trials. The IND application must be submitted by a company or organization known as a Sponsor. Several topics can be covered in a pre-IND meeting with the FDA:

• The manner in which clinical investigations are supported by animal research

•The planned procedure for carrying out the clinical trial

• The investigational drug's chemistry, production, and management A conference like this will assist the sponsor in planning animal research, collecting information, and creating the clinical protocol in accordance with FDA recommendations.[38]

Types of IND

• An Investigator IND:

This is presented by a physician that in addition to initiating and conducting the test, the physician can submit an application for the investigation and s ubmit an application for the investigation to investigate approved drugs or new uses or fraudulent treatments for another patient population. Use in Eme rgency Healing: Presented in FDA reviews and final clinical research for promising laboratory drugs in clinical studies of serious or immediate life-threatening diseases. The two IND categories are commercial and research (commercially). The IND application must include three main types of infor mation:

(1) Manufacturing Information;

(2) Clinical Protocols and Investigator Information; and

(3) Animal Pharmacology and Toxicology Studies.

Before beginning any clinical studies, the sponsor must wait 30 calendar days following the submission of the IND. The FDA has the chance to examine the IND for safety during this period to ensure that research participants won't be exposed to unreasonable risk.

IND Content and Format [35, 39]

The structure and content criteria for IND applications are explained in Section 312 of the Federal Regulations 21 Code (CFR). In the following order, " New drug application under clinical trial" must be submitted by a sponsor (commercial unit) or by an investigator performing the clinical test.

1. FDA Form 1571

2. Contents table

3. The statement of introduction and the plan of research

4. The brochure for the investigator

5. Procedures

6. Information on chemistry, manufacturing, and control (CMC)

7. Information on pharmacology and toxicology

8. Prior human experience

9. Extra details via New Drug Application (NDA



Figure 3: investigational new drug application approval process

A New Drug Application

In clinical research, if treatment is usually safe and effective and the patient does not expose unnecessary risks, manufacturers apply the New Drug App lication (NDA), the official requirement for US drug production and marketing. A new drug application must be submitted to approve the commercializ ation of new drugs in the United States. Results of clinical studies with effectiveness and security are included in the NDA and IND information. The re view process must receive your NDA within 60 days from the FDA. [40.41]

Contents and Format of an NDA [35]

Two copies of the application are: (1) Archival copy and (2) Review copy.

1). Archival Copy:

It includes copies of tabulations and clinical research case report forms, and FDA reviewers can use it as a reference to find material not included in the review copy. It includes the following components:

a). FDA 356 application form

b). Index

c). Synopsis

d). Sections on technology:

Moreover, the following sections were typed:

1. Chemistry, Manufacturing, and Controls;

2. Non-clinical Pharmacology and Toxicology;

3. Human Pharmacokinetics and Bioavailability;

4. Microbiology;

5. Clinical Data; and

6. Statistical Section

7 Paediatric Use:

e) Samples and Labeling

f). Forms for case reports

2). Review Copy:

Every folder has a different binding for each technical element. The following should be included in every technical section:

a). Index

b). FDA Form 356 h

c)copy a duplicate of the cover letter

d). Authorization letters

e). A copy of the application summary The FDA is permitted to meet with the sponsor at least twice: once at the conclusion of Phase 2 clinical trials and again before to the submission of an NDA, often known as a pre-NDA meeting. After evaluating the study's findings, the review panel will decide whether to accept the application. Throughout the evaluation process, the sponsor and the FDA communicate often [42].



Figure 4: Flow Chart of New Drug Application

Abbreviated New Drug Application (ANDA) [43]

ANDA has been proven safe and effective in the past, and has been used in products that have the same or very similar components as similar active co mponents, dosage forms, efficacy, management, use, and labeling. These drugs are called generics and must adhere to comparable drug and biotechnolo gy standards. ANDAs will be checked and approved by the drug evaluation and general drug lab if submitted. andas format and content[35]

1. The application
2. Contents table
3. The foundation for the ANDA submittal
4. Terms and conditions of usage
5. Ingredients that are active
6. Administration route, dose, and strength
7. Bioequivalence

8. Labeling

9. Manufacturing, control, and chemistry

10. Bioavailability and pharmacokinetics in humans

11. Illustrations

12. Methods of analysis

13. Forms and tabulations for case reports.

"Partition of generic bioexhabarzbulo in July 1992" published the guidelines for statistical procedures for bioequivalence studies using a standard cross over design of two treatments that provides reliable statistical analysis guidelines for biokey valence assessments. Validity assessments of effectiveness can be considered for validity. The FDA later compared pharmacokinetic metrics with the "Biobioequivalz Study" [44, 46, 47] and the "in vivo bioequi valz Study." Additionally, we provide a review of the therapeutic equivalence of prescription drug elements from many sources with the same active in gredient. [45, 48]



Figure 5: Flow Chart of Abbreviated New Drug Application

Supplemental New Drug Application (SNDA)

All significant changes to the terms described in the application must be approved by submitting additional NDAs or ANDAs after the NDA or ANDA has been approved [26]. CER must approve such changes. B. People involved in materials and packaging [48]. Newly used approvals for previously ap proved drugs that fall within this group are superior to innovation because there are fewerresources to check than the original use permit [49].

Drug approval in Europe

When searching for permission to commercialize new drugs in Europe, sponsors can choose a centralized procedure, a decentralized process, a mutual detection procedure, or a national sanctioning procedure. These two processes are clinical research applications and applications for marketing approval . In July 2013, the European Union had 28 member states. Applications for marketing permits are granted at both member states and central levels, whil e clinical research applications in member countries have been approved. [51-53]

- **National authorization procedure**

Each EU Nation has its own process of approving marketing applications for new drugs. For more information about the approval process, sponsors can access the websites of regulatory authorities in any country that they wish to receive marketing permission. That is if the drug is approved in a single m ember state. However, to obtain permission from another Member State, applicants must submit a separate application using data approved by previous Member States of the mutual identification process. Additionally, if the applicant is not registered with the association, the application is approved usin g a decentralized process. [50]

- **Decentralized procedure**

  Through this approach, companies can simultaneously apply for approval in several EU countries for products that are not permitted in EU countries and do not fall under the essential list of essential medicines in a centralized system. The decisions made by RMS and CMS in thi s distributed process are based on assessment reports created by RMS and all comments created by CMS and continue when the marketing approval is issued.
  Usually, this refers to products that have not yet been approved in EU countries.
  210 days have passed. [1]

- **Mutual Recognition Procedure**

  In the Concerned member states (CMS) other than the Reference member state (RMS), where the medicine has already received approval, applicants can acquire a marketing license through the Mutual Recognition process.

  • The applicant sends the same dossier, complete with all necessary documents, to each EU member state where they wish to obtain marketing authorization.

  • Other Member States (who then become the "CMS"), to whom applications have also been submitted, are notified as soon as one Member State agrees to review the medical product (so it becomes the "RMS").

  • RMS provides other states with its own findings.

  • The primary consumer of this kind of medicine approval process is the generic industry. The duration of this treatment could reach 390 days.

- **Centralized procedure**

  The European Medicine Agency is responsible for approval of European Medicine. With its main office in London, UK, the EMA is a decentraliz ed institution of the EU. The centralized system is responsible for conducting scientific reviews of applications for approval of marketing of Euro pean medicines. Drug marketing applications intended for human use will be considered by the Medical Products Committee for use in humans (CHMP). To take into account assessments as part of the central procedure, the following requirements must be met with the product:

  Very biologically produced using hybridoma and monoclonal antibody technology, recombinant technology, and regulated expression of genes en coding eukaryotic physiologically active proteins, including transformed mumaria cells. Ingredients of the following diseases: AIDS, diabetes, ca ncer, neurodegenerative diseases, autoimmune diseases, viral infections and other orphanages. Additional new active substances can be accepted a s part of the central procedure if the product can demonstrate that significant therapeutic, scientific, or technological innovation is expressed or tha t the approval of the community within the community is in the greatest benefit of the community in the community, depending on the applicant's request. [5]

Pre-submission process

Sponsors must notify EMA of its submission plan and month of submission at least seven months prior to submitting a Marketing Approval Applicatio n (MAA). Many of the documents contained in this pretransfer explain sponsor discussions regarding application submissions regarding centralized pro cesses. After reviewing the ministries, the EMA will notify the sponsor of its decision to accept the MAA.

Selection of rapporteur/co-rapporteur

The reporter is the national regulator of the European Union. CHMP members are called reporters (reviewers) and co-
proporers (if necessary). Reporters are selected based on objective criteria to ensure optimal use of objective scientific opinions and the available capabi lities of EMA. Reporting tasks include developing CHMP assessment reports and ending the scientific overview when joint reports are used. The proce ss of choosing a reporter or co-rotation is usually started in a CHMP session. [54]

Product naming

If they do not violate brand law, the names of drug sponsors in all EU countries should be the same. The proposed name must be submitted by the spon sor at least 4-6 months before the marketing application for approval, but will be submitted in the last 12 months.

Drug approval in Australia

Federal government's therapeutic cargo management is responsible for the regulation of medication and medical devices. Recipes and over-the-counter medications that meet Australia's standards of quality, security and effectiveness are included in the Australian therapeutic products register. Yo u can list or register your medications. After a comprehensive evaluation, registered products will receive an Aust-R number.
One of the goals of the Treatment Products Act from 1989, monitored by the TGA, is to establish a national system of controls related to the quality, se curity, effectiveness and timely availability of treatment products used in Australia, whether they are used in Germany or not. [50,43]

Prescription medicines

Since the foundations of 1963, Australia's method of assessment of new active ingredients, new management channels, and extensions of recognized us es (or "adaptive") has been changed from products currently on the market. This system was used to analyze most of the prescription drugs currently in use. Indepth information on animal pharmacology and toxicological studies, human clinical research demonstrating product security and efficacy in inte nded use, and substance integration should be included in the application of new active substances at recent registrations. Registration in Australia is for ever. The product remains registered until there is a reason to cancel or the sponsor stops marketing. Long before the evaluation procedure, several acti ve ingredients, including aspirin, were submitted in Australia. Registration will not be considered if there are no security concerns or suggestions for us e. In Australia, numerous prescription drugs are copies of copyrighted products, usually produced by other manufacturers. The same manufacturing reg ulations and quality standards apply to these general products. However, there is no need for a complete demonstration of effectiveness and security. O nly evidence that the wording is equivalent to the original product. 1Comparative analysis of products in human subjects is usually part of the Bio Equi valz study, but for certain products, benchtop dissolution testing is appropriate. Comparable tests of human volunteers should be verified for the promis e of modified release formulations.

Over-the-counter medicines

Today, in reality, all active ingredients were introduced as part of the prescription drug -
Counter Counter treatment. The active ingredient is usually a prescription drug and should be used for at least two years before it can be used for treatm ents that are not covered by the prescription drug. OTCNot all active ingredients used in drugs can be used in prescription drugs. Usually there is less n ew data to support effectiveness and security. TGA evaluates the security, effectiveness, and quality of new counter drugs. Rules governing things like production conditions and quality are very similar to the products of prescription drugs.
Complementary therapy forms almost the entire list of drugs. This includes traditional drugs such as Ayurveda and traditional Chinese medicines, herba l remedies, most vitamin and mineral additives, other nutritional additives, and aromatherapy oils. The listed product categories were created in 1991 an d regulated products that by definition had little chance of adverse effects. Although Tr's articles have not been considered prior to entry to ARTG, they must adhere to comparable manufacturing requirements, including certification of excellent production practices. The main safety measures for these p roducts are provided by the 1990 Treatment Products Regulations. Aust Drugs are as follows:

• Not be subject to national regulations that contain compounds that are prohibited from importation, come from endangered species, or limit access to a variety of pharmaceuticals (Standard for the Uniform Scheduling of pharmaceuticals and Poisons).

• Adhere to lists of approved ingredients, which include vitamins, minerals, and compounds that have been certified listable.

• Other limitations might exist, like dosage limitations, thorough label warnings, and prohibitions on specific plant parts or processing methods. Certain herbs are forbidden.

•Unless the product was used to heal serious conditions, the original method of regulating AustL products required no evidence to ensure the manufactu rer's requirements.
We considered that in many cases, impossible promises were made on the product, leading to the introduction of rules in April 1999 that required spons ors of OUST-
L objects to provide evidence of their claims. TGA has the right to apply for this proof and confirm if any issues or complaints arise at any time during t he life of the product. TGA can remove the product from the list if detection is not sufficient. Approximately 20% of the new list are randomly selected and compliance with list requirements is carefully evaluated. 3. Registration (AUST R status) can be permitted if there is an indication that AUST-
L drugs are effective. [45]

Exemptions Medicines

Currently, TGA regulations do not apply to drug therapy (except gene therapy) prescribed to a particular person or manufactured on-
site. This exception is used by certain pharmacies and clinics to provide a significant number of patients in a particular pharmacy. Occasionally, claims about unique features are made, including "slow public products." The TGA does not evaluate or regulate such factors. Homeopathic and traditional pra ctitioners of herbal medicines that prescribe the drug individually are also excluded. Additionally, some drugs do not need to be included in the ARTG. Homeopathic therapy is probably the most important thing. This exemption from the TGA supervision has been sold for allegedly suspected homeopath

ic drugs such as homeopathic melatonin and somatropine.
It was therefore suggested that TGA regulates homeopathic products more closely. As expected, this focuses on ensuring that these products are manufa ctured according to the same production standards as traditional medicines and are designed with the adoption of homeopathic principles and practices. [50]

Conclusion

Before pharmaceutical items are put on the market, their safety, effectiveness, and quality are guaranteed by the stringent and complex medication approval process. The unique practices and legal frameworks in several important regions are highlighted in this overview, including the US (FDA), India (CDSCO), Europe (EMA), and Australia (TGA). Although every nation has different needs and deadlines, the basic objective is always the same: to safeguard public health by abiding by strict ethical and scientific guidelines.

Preclinical research, clinical trials (Phases 0–IV), and post-marketing surveillance are some of the crucial steps in the process. The focus on evidence-based review is universal, notwithstanding differences in submission formats (e.g., CTD, eCTD) and approval processes (e.g., centralized, decentralized, or mutual recognition in the EU). Challenges like lengthy procedures, exorbitant expenses, and regional differences highlight the necessity of more international harmonization of regulatory norms. Efforts to streamline procedures while upholding safety standards include the Common Technical Document (CTD) and adaptive licensing.

Future developments that promise to further improve efficiency and creativity include AI-driven drug development and the integration of real-world evidence. To guarantee patient safety and therapeutic efficacy, it is still crucial to strike a balance between speed and careful evaluation. The pharmaceutical industry can continue to provide patients throughout the world with life-saving drugs in a timely and safe manner by encouraging regulatory authorities to collaborate and implementing best practices.

In conclusion, maintaining the highest standards of public health while accelerating global drug research, cutting down on redundancies, and expanding access to modern-edge therapeutics requires an understanding of and consistency with international drug approval processes.

REFERENCE

1. Prajapati V, Goswami R, Makvana P, Badjatya JK. A review on drug approval process for US, Europe and India. Int J Drug Regul Aff. Available from: www.ijdra.com
2. Dinesh Pendharkar MD and Nagalakshmi Ananda Padmanabhan: The Drug Approval Process in India (26thmay, 2016) from https://am.asco.org/daily-news/drug-approvalprocess-india
3. Rawat S, Gupta A. Regulatory requirements for drug development and approval in United States: A review. *Asian J Pharm Res.* 2011;1(1):01-06.
4. Lahiry S, Sinha R, Choudhury S, Mukherjee A, Chatterjee S. Paradigm shift in clinical trial regulations in India. Indian J Rheumatol. 2018;13(1):51.
5. Karve AV, Sheth AP, Perveen SS. An analysis of drug approvals in india over past 10 years. J Res Educ Indian Med. 2014;20(3-4):141-52
6. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426-37. doi: 10.1038/clpt.2011.345.
7. Hervey TK, McHale JV. Brexit and health law. Health Econ Policy Law. 2020;15(3):257-269. doi: 10.1017/S1744133120000206.
8. Bennett M, Mullard A. Real-world evidence in drug development. Nat Rev Drug Discov. 2021;20(4):252-253. doi: 10.1038/d41573-021-00028-4.
9. McEwan J. A history of therapeutic goods regulation in Australia [Internet]. Canberra: Therapeutic Goods Administration; 2007 [cited 2024 Jan 15]. Available from: https://www.tga.gov.au/history-therapeutic-goods-regulation-australia
10. Deore, AB, Dhumane JR, Wagh HV, Sonawane RB, The Stages of Drug Discovery and Development Process. Asian Journal of Pharmaceutical Research and Development. 2019; 7(6):62-67, DOI: http://dx.doi.org/10.22270/ajprd.v7i6.616.
11. Shayne CG. Introduction: drug Discovery in the 21stCentury. Drug Discovery Handbook, Wiley Press, 2005; 1-10.
12. Kumar KK, Jeya Ananthi J, Nasar S, Venkateswarlu BS, Venkatachalam T. A Textbook of Pharmaceutical Regulatory Science. New Delhi: S. Vikas & Company.
13. Rao VS, Srinivas K. Modern drug discovery process: An in silico approach. *J Bioinformatics Sequence Anal*. 2011;2(5):89-94. Available from: http://www.academicjournals.org/JBSA. Accepted 3 June.
14. Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003). "Hit and lead generation: Beyond high-throughput screening." Nat. Rev. Drug Discov., 2(5): 369-378. May.

15. Patidar AK, Selvam G, Jeyakandan M, Mobiya AK, Bagherwal A, Sanadya G, Mehta R. Lead Discovery and lead optimization: A useful strategy in molecular modification of lead compound in analog design. International journal of drug design and discovery. 2011; 2(2):458- 463.
16. Klaus ODVM, Peter GU, Nzel DVM, Rolf BMD (2001). "Preclinical Testing Strategies." Drug Inf. J. 35: 321–336
17. Barile FA. Pri. nciples of Toxicological Testing. CRC Press, USA, 2008.
18. Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical trials. 4th ed. New York: Springer Science and Business Media LLC; 2010.
19. Faqi AS. A comprehensive guide to toxicology in preclinical drug development. Waltham, MA: Elsevier; 2013.
20. Darji P, Patel J, Patel B, Khatri V, Joel Fnu PI, Nalla S. Comprehensive review on drug discovery and development process. *J Chem Health Risks*. 2024;14(3):2558-2565. doi:2251-6727.
21. Fitzpatrick S. The clinical trial protocol. Buckinghamshire: Institute of Clinical Research; 2005
22. DiMasi J. Risks in New Drug Development: Approval success Rates for Investigational Drugs. Clinical Pharmacology & Therapeutics, 2001; 297-307.
23. Friedhoff L. New Drugs: An Insider 's Guide to the FDA 's New Drug Approval Process for Scientists, Investors and Patients. New York, NY: PSPG Publishing; 2009.
24. Adams CP, and Brantner VV. New Drug Development: Estimating entry from human clinical trials. Bureau of Economics Federal Trade Commission. 2003.
25. Mimansha Patel, Kunjal Patel (2013). An overview to CTD, ACTD and Indian requirements for dossier submission: Differences and similarities. Indo American Journal of Pharmaceutical Research. 3(2):1746-1751.
26. Jatin Patel, Krunal Parikh, Dhiren Shah: New drug approval procedure in India. ReferenceId: pharmatutor-art-1531available in https://www.pharmatutor.org/articles/new-drug approval-procedure-India
27. Central Drugs Standard Control Organization, Ministry of Health. Guidance for Industry. cdsco.nic.in/writereaddata/CDSCOGuidanceForIndustry.pdf. Accessed January 7, 2016.
28. Chirag Shah, Param Dave: Regulatory Approval in India: An Updated Review [04 th May 2016 from http://www.appliedclinicaltrialsonline.com/regulatory-approval-indiaupdated-review.
29. Schedule Y. Amendment Version 2005, Drugs and Cosmetics Rules, 1945;503-47
30. Jawahar *, Vidhya Lakshmi. T, Regulatory Requirements for the Drug Approval Process in the US, Europe, and India. Journal of Pharmaceutical Science and Research 2017; 9(10):1943-1952.
31. Lachman L, Liberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Varghese Publishing House; 1987.
32. Van Norman G, et al. Drugs, Devices, and the FDA: Part 1. J Am Coll Cardiol Basic Trans Science. 2016 Apr, 1 (3) 170–179.
33. Pisano DJ, David M. Overview of Drug Development and the FDA. In: Pisano DJ, FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics. Florida: CRC Press LLC 2004; pp. 2-20.
34. Ali A, Ali J, Sahni JK, Qureshi J. United States of America. In: International Licensing. New Delhi: Hamdard University, Excel Books Pvt Ltd 2007; pp. 51-110.
35. Randall B IV. The U.S. Drug Approval Process: A Primer; Congressional Research Service; The Library of Congress. Available from: http://www.law.umaryland.edu/marshall/crsreports/crsdocu ments/RL30989.pdf. 2001.
36. William RP, Raymond DM. Drug Regulatory Affairs. In: Lachman L, Lieberman HA, The theory and practice of Industrial Pharmacy. India: CBS Publishers and Distributors 2009; pp. 856-882.
37. Peck GE, Poust R. Food and Drug Laws that affect Drug Product Design, Manufacture and Distribution. In: Gilbert SB, Christopher TR, Modern Pharmaceutics. 4th ed, New York: Marcel Dekker Inc 2002; pp. 930-46
38. Food and Drug Administration. Investigational New Drug Application. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/ [Accessed on 02/11/2013]
39. Troetel WM. Investigational New Drug Application and the Investigator's Brochure. In: Richard AG, New Drug Approval Process: Accelerating Global Registrations; 4th ed. New York: Marcel Dekker Inc 2004; pp. 54-86.
40. Food and Drug Administration. New Drug Application. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ [Accessed on 02/11/2013].

41. Maria LW. Research. In: Alfonso R Gennaro, Remington: The Science and Practice of Pharmacy; 8th ed. Baltimore: Lippincott Williams and Wilkins 2000; Vol. 1: pp. 87-8.

42. Swati R, Akhilesh G. Regulatory requirements for drug development and approval in united states: a review. Asian J Pharm Res 2011; 1(1): 1-6.

43. Food and Drug Administration. Abbreviated New Drug Application. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/

44. Draft guidance for industry on in vivo bioequivalence studies based on population and individual bioequivalence; division of bioequivalence, office of generic drugs, center for drug evaluation and research, food and drug administration, Rockville, Maryland. Available from: http://www.fda.gov/downloads/drugs/scienceresearch/ucm301280.pdf [Docket No. 97D–0433], 1997.

45. Chow SC. Individual Bioequivalence – A Review of FDA Draft Guidance; Stat Plus, Inc. Available from: http://stat.fi/isi99/ proceedings/arkisto/varasto/chow0795.pdf. May 7, 1999.

46. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.html [Accessed on 02/11/2013]

47. Knoben JE, Scott GR, Tonelli RJ. An overview of the FDA publication: approved drug products with therapeutic equivalence evaluations. Am J Hosp Pharm 1990; 47(12): 2696-700.

48. Supplement: drugs @fda glossary of terms; drug approvals and databases; drugs, FDA. Available from: http://www.fda.gov/Drugs/ InformationOnDrugs/ucm079436.htm#S [Accessed on 02/11/2013]

49. Joseph AD. Innovating by developing new uses of alreadyapproved drugs: trends in the marketing approval of supplemental indications. J Clin Ther 2013: 35(6): 808-18

50. Mulaje SS, Birajdar SM, Patil BR, Bhusnure OG. Procedure for drug approval in different countries: A review. J Drug Deliv Ther. 2013;3(2):233-238. Available from: http://jddtonline.info

51. IRA RB, Robert PM. The Pharmaceutical Regulatory Process. 2nd ed. Informa healthcare; 2008. p. 46-48.

52. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc.; 2008. p. 212- 220.

53. IRA RB, Robert PM. The Pharmaceutical Regulatory Process. 2nd ed. Informa healthcare; 2008. p. 49-51.

54. Lund J. Regulatory processes for medicinal products in the European Union. *Regul Aff J*. 2015;34(1):12-22.

55. Sangavi C. Regulatory requirements for the new drug approval process in different countries. Int J Drug Regul Aff. 2013-2023; Available from: www.ijdra.com